TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02005588
Drug: iron salt (ferrous fumarate)
Normalized name: iron bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
Study: NCT01043211
Drug: Lidocaine Hydrochoride Injection, without epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
Study: NCT04699669
Drug: CBL-514, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.
Study: NCT01043211
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
Study: NCT01043211
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
Study: NCT03201614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
Study: NCT00371020
Drug: low molecular weight heparin, 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00441727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT00844012
Drug: Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
Study: NCT01702025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow corn meal in gel capsules
Study: NCT03053401
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
Study: NCT04741295
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
Study: NCT00533169
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
Study: NCT03802240
Drug: IBI305
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg IV Q3W
Study: NCT00704938
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60mg/kg/day (Days-7,-6)
Study: NCT03802240
Drug: Placebo1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo1 IV Q3W
Study: NCT04572698
Drug: LY09004
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
Study: NCT03321890
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, 50mg / day,after lunch
Study: NCT03321890
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, 10mg / times, once a week,after breakfast
Study: NCT04002258
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
Study: NCT00038103
Drug: Celecoxib + Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
Study: NCT05482828
Drug: JGT (Jaeumgeonbi-Tang) tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
Study: NCT05482828
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
Study: NCT02784327
Drug: PRF110
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03132324
Drug: INCB059872
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB059872 tablets
Study: NCT02200952
Drug: recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant LH twice/day for 10 days from pick up
Study: NCT03234816
Drug: Norepinephrine 0.05 mcg /Kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Study: NCT03234816
Drug: Norepinephrine 0.1 mcg /Kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Study: NCT03234816
Drug: Norepinephrine 0.15 mcg /Kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Study: NCT03254394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water will be administered as active comparator.
Study: NCT03254394
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days.
Study: NCT02473562
Drug: Placebo (for varenicline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet 1 mg BID
Study: NCT02317016
Drug: AZD9291 tablet dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
Study: NCT02317016
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
Study: NCT01670110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be injected once per month
Study: NCT00966199
Drug: anti-hypertensive medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
Study: NCT02300259
Drug: LY2623091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02300259
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01285934
Drug: intensive insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
Study: NCT04042324
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
Study: NCT02804126
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Study: NCT00889512
Drug: Luveris fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luveris 75IU daily throughout ovarian stimulation
Study: NCT01390402
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 by vein Days 1, 3 and 6 post transplant.
Study: NCT00746863
Drug: 0.125% Marcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
Study: NCT02737124
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be given 24 hours before scheduled surgery.
Study: NCT01066728
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00655629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
Study: NCT00654082
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
Study: NCT00534924
Drug: Vit C
Normalized name: M-Vit Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02511886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched tablets
Study: NCT01301313
Drug: Conventional intensified inotropic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
Study: NCT00003727
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01776606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Dose B; dose applied to the lateral canthal lines
Study: NCT00047515
Drug: Alcon Investigational Agent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04252261
Drug: placedo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
Study: NCT02456454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01091142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
Study: NCT03235947
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
Study: NCT00127179
Drug: Comparator: placebo / Duration of Treatment: 48 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02155777
Drug: OrthoNovum 1/35
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04533139
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens
Study: NCT00657163
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine per os 20 mg daily
Study: NCT00657163
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo per os daily
Study: NCT02685033
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04577469
Drug: Maldox tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study: NCT04577469
Drug: G-COSPE® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study: NCT00971074
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
Study: NCT03328117
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral capsule
Study: NCT02124213
Drug: 30 mg PF-06412562
Normalized name: CODEINE PO4 30MG/ML (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive a single dose of 30 mg PF-06412562
Study: NCT02008734
Drug: PD0332991
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01303835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized patients received placebo to be taken every night before bed.
Study: NCT00423007
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00423007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01485328
Drug: AMARGOL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: per oral solution, 40 mL single dose
Study: NCT00566462
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for for 14 days followed by 4 mg/d for 14 days
Study: NCT00832416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Placebo tablet daily.
Study: NCT00058188
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04523467
Drug: Anti-angiogenic Targeted Drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
Study: NCT00856817
Drug: L-arginine + heme arginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine first, heme arginate second three day treatment
Study: NCT00856817
Drug: Heme arginate + L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme arginate first, L-arginine second three day treatment
Study: NCT02238158
Drug: Atrovent® inhalets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04776889
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
Study: NCT00693693
Drug: hydrocortisone 17-butyrate 0.1% Ointment preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply medication twice a day to affected areas of atopic dermatitis
Study: NCT00693693
Drug: hydrocortisone 17-butyrate 0.1% Lipocream preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply medication twice a day to affected areas of atopic dermatitis
Study: NCT01985750
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation
Study: NCT00087334
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02995473
Drug: NP000888
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 µg/g topical (BID) for 24 weeks
Study: NCT02995473
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical (BID) for 24 weeks
Study: NCT05060198
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
Study: NCT03934203
Drug: Placebo matching to BI 409306
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT03163173
Drug: GC4419
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg (\~100 μCi) dose of \[14C\]GC4419
Study: NCT00995605
Drug: AMAP102
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMAP102 or Placebo
Study: NCT01810380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily as tablets and capsules, orally
Study: NCT01537133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Powder Inhaler: Placebo
Study: NCT04356872
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADM, 60mg/m2, iv, d1
Study: NCT00876044
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous route
Study: NCT04257851
Drug: Theophylline Anhydrous Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline tablet (150 mg/12h)
Study: NCT04131829
Drug: Fluoxetine - delayed treatment
Normalized name: fluoxetine Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
Study: NCT02915055
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
Study: NCT02915055
Drug: standard oxycodone/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04619914
Drug: Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
Study: NCT01362491
Drug: Ibuprofen Sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
Study: NCT01362491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of placebo
Study: NCT02491736
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5% ketoprofen gel
Study: NCT03778593
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
Study: NCT02337010
Drug: Vasopressor
Normalized name: Vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
Study: NCT04479449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study: NCT02674347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV matching the Investigational drug
Study: NCT01749787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via infusion once per week for 5 weeks
Study: NCT01159015
Drug: KetoNaph
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution administered BID for 6 weeks
Study: NCT01159015
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
Study: NCT04577430
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
Study: NCT01456169
Drug: Azilsartan medoxomil - chlorthalidone
Normalized name: azilsartan medoxomil / chlorthalidone Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
Study: NCT01942174
Drug: Methotrexate - Immediate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
Study: NCT01942174
Drug: Methotrexate - Delay
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13
Study: NCT01687101
Drug: STOPAIN topical gel
Normalized name: Stopain Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
Study: NCT02159976
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500mg bid
Study: NCT02159976
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline 1000mg bid
Study: NCT01165294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes